UMIN ID: C000000092
Registered date:30/08/2005
Phase II study of ABVd therapy for the previously untreated patients with stage II to IV Hodgkin' s disease (JCOG 9305, LSG14)
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | previouly untreated advanced stage Hodgkin lymphoma (stage II, III, IVy) |
| Date of first enrollment | 1993/12/01 |
| Target sample size | 108 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | polychemotherapy, raiotheraoy |
Outcome(s)
| Primary Outcome | complete response rate (%CR+%Cru), progression-free survival |
|---|---|
| Secondary Outcome | toxicity, 5-year surivival, prognostic foctor |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | 70years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1.severe comorbidity (e.g. severe infectious disease, heart failure, respiratory dysfunction, hepatic failure, liver cirrhosis, renal failure, active peptic ulcer, insulin dependent diabetes mellitus 2. other active neoplasms 3. psychological disease 4. expected survival ; less than 3 months 5. Pregnant women 6. Past history of myocardial infarction 7. Positive for HTLV-1 |
Related Information
| Primary Sponsor | Japan Clinical Oncology Group(JCOG) |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Ministry of Health, Labour and Welfare |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Michinori Ogura, MD, PhD |
| Address | Myokencho 2-9, Showaku, Nagoya, Aichi 466-8650, Japan Japan |
| Telephone | |
| JCOG_sir@ml.jcog.jp | |
| Affiliation | JCOG9305 Coordinating Office Department of Hematology, Nagoya Daini Red Cross Hospital |
| scientific contact | |
| Name | Masanori Shimoyama, MD, PhD |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan Japan |
| Telephone | |
| Affiliation | National Cancer Center Hospital Department of Medical Oncology |